Gene therapy in autoimmune diseases: Challenges and opportunities

Patrick S Leung, Amy Dhirapong, Ping Yi Wu, Mi Hua Tao

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Clinical treatment of autoimmune disorders presents a special challenge. For decades, most clinical regimens in autoimmunity has been largely symptomatic and non-disease specific. Although data from vigorous research has lead to accumulating knowledge on the pathogenic and immunological mechanisms of many autoimmune diseases, their direct clinical applications have been sparse. Advances in biotechnology have laid the groundwork for potent and specific molecular targeting therapies by gene therapy, and have just begun to be investigated in the treatment of autoimmune disorders. Such work has been largely based on the availability of well-established animal models of common autoimmune disorders, and the efficacy of strategic approaches initially investigated and validated in these models. Although these preclinical animal model studies have provided the proof-of-concept for multiple potential applications, human clinical trials on gene therapy in autoimmunity are still at its infancy. The recent success of Phase I/II clinical trials of gene therapy in rheumatoid arthritis and multiple sclerosis, development of cutting edge technology in target identification, as well as gene delivery systems have now set the stage for a more thorough and vigorous pace in the near future to advance this exciting field.

Original languageEnglish (US)
Pages (from-to)170-174
Number of pages5
JournalAutoimmunity Reviews
Volume9
Issue number3
DOIs
StatePublished - Jan 2010

Fingerprint

Genetic Therapy
Autoimmune Diseases
Autoimmunity
Animal Models
Gene Transfer Techniques
Phase II Clinical Trials
Clinical Trials, Phase I
Biotechnology
Multiple Sclerosis
Rheumatoid Arthritis
Therapeutics
Clinical Trials
Technology
Research

Keywords

  • Clinical trials
  • Gene therapy
  • Immunomodulation
  • Multiple sclerosis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Gene therapy in autoimmune diseases : Challenges and opportunities. / Leung, Patrick S; Dhirapong, Amy; Wu, Ping Yi; Tao, Mi Hua.

In: Autoimmunity Reviews, Vol. 9, No. 3, 01.2010, p. 170-174.

Research output: Contribution to journalArticle

Leung, Patrick S ; Dhirapong, Amy ; Wu, Ping Yi ; Tao, Mi Hua. / Gene therapy in autoimmune diseases : Challenges and opportunities. In: Autoimmunity Reviews. 2010 ; Vol. 9, No. 3. pp. 170-174.
@article{041b3ca20fb642879a2982199d970a90,
title = "Gene therapy in autoimmune diseases: Challenges and opportunities",
abstract = "Clinical treatment of autoimmune disorders presents a special challenge. For decades, most clinical regimens in autoimmunity has been largely symptomatic and non-disease specific. Although data from vigorous research has lead to accumulating knowledge on the pathogenic and immunological mechanisms of many autoimmune diseases, their direct clinical applications have been sparse. Advances in biotechnology have laid the groundwork for potent and specific molecular targeting therapies by gene therapy, and have just begun to be investigated in the treatment of autoimmune disorders. Such work has been largely based on the availability of well-established animal models of common autoimmune disorders, and the efficacy of strategic approaches initially investigated and validated in these models. Although these preclinical animal model studies have provided the proof-of-concept for multiple potential applications, human clinical trials on gene therapy in autoimmunity are still at its infancy. The recent success of Phase I/II clinical trials of gene therapy in rheumatoid arthritis and multiple sclerosis, development of cutting edge technology in target identification, as well as gene delivery systems have now set the stage for a more thorough and vigorous pace in the near future to advance this exciting field.",
keywords = "Clinical trials, Gene therapy, Immunomodulation, Multiple sclerosis, Rheumatoid arthritis",
author = "Leung, {Patrick S} and Amy Dhirapong and Wu, {Ping Yi} and Tao, {Mi Hua}",
year = "2010",
month = "1",
doi = "10.1016/j.autrev.2009.10.004",
language = "English (US)",
volume = "9",
pages = "170--174",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Gene therapy in autoimmune diseases

T2 - Challenges and opportunities

AU - Leung, Patrick S

AU - Dhirapong, Amy

AU - Wu, Ping Yi

AU - Tao, Mi Hua

PY - 2010/1

Y1 - 2010/1

N2 - Clinical treatment of autoimmune disorders presents a special challenge. For decades, most clinical regimens in autoimmunity has been largely symptomatic and non-disease specific. Although data from vigorous research has lead to accumulating knowledge on the pathogenic and immunological mechanisms of many autoimmune diseases, their direct clinical applications have been sparse. Advances in biotechnology have laid the groundwork for potent and specific molecular targeting therapies by gene therapy, and have just begun to be investigated in the treatment of autoimmune disorders. Such work has been largely based on the availability of well-established animal models of common autoimmune disorders, and the efficacy of strategic approaches initially investigated and validated in these models. Although these preclinical animal model studies have provided the proof-of-concept for multiple potential applications, human clinical trials on gene therapy in autoimmunity are still at its infancy. The recent success of Phase I/II clinical trials of gene therapy in rheumatoid arthritis and multiple sclerosis, development of cutting edge technology in target identification, as well as gene delivery systems have now set the stage for a more thorough and vigorous pace in the near future to advance this exciting field.

AB - Clinical treatment of autoimmune disorders presents a special challenge. For decades, most clinical regimens in autoimmunity has been largely symptomatic and non-disease specific. Although data from vigorous research has lead to accumulating knowledge on the pathogenic and immunological mechanisms of many autoimmune diseases, their direct clinical applications have been sparse. Advances in biotechnology have laid the groundwork for potent and specific molecular targeting therapies by gene therapy, and have just begun to be investigated in the treatment of autoimmune disorders. Such work has been largely based on the availability of well-established animal models of common autoimmune disorders, and the efficacy of strategic approaches initially investigated and validated in these models. Although these preclinical animal model studies have provided the proof-of-concept for multiple potential applications, human clinical trials on gene therapy in autoimmunity are still at its infancy. The recent success of Phase I/II clinical trials of gene therapy in rheumatoid arthritis and multiple sclerosis, development of cutting edge technology in target identification, as well as gene delivery systems have now set the stage for a more thorough and vigorous pace in the near future to advance this exciting field.

KW - Clinical trials

KW - Gene therapy

KW - Immunomodulation

KW - Multiple sclerosis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=72149129189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149129189&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2009.10.004

DO - 10.1016/j.autrev.2009.10.004

M3 - Article

C2 - 19854300

AN - SCOPUS:72149129189

VL - 9

SP - 170

EP - 174

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 3

ER -